Skip to content

Femoral Bone Metastases

A Prospective Cohort Study of the Role of Surgery and/or Radiotherapy for Bone Metastases of the Femur at High Risk of Pathological Fracture

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01428895
Enrollment
180
Registered
2011-09-05
Start date
2009-03-01
Completion date
2027-02-01
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Metastatic Malignant Neoplasm to Femur, Risk of Fracture

Keywords

Bone Metastases, Femoral Metastases

Brief summary

Bone is a common site of metastasis for a range of malignancies. Bone metastases have the potential to cause significant morbidity including pain, impairment of ambulation and reduced functional independence. Previous research has shown that pathological fractures are observed in 9 to 29 percent of patients with long bone metastases, and a high proportion of these require surgical intervention to relieve pain and restore function. The goal of this study is to describe the clinical outcomes of patients with femoral metastases at high risk of pathological fracture. Patients referred for treatment of femoral metastases at high risk of fracture will be followed prospectively after undergoing with surgery (± post-operative radiotherapy), or radiotherapy alone. Patient and disease characteristics, ambulatory status and limb function will be documented before treatment. These Clinical outcomes of participants in each treatment group will be measured 6 weeks after treatment, and 3- and 6 months after enrolment, with particular reference to patient-reported outcomes relating to pain, ambulatory status, limb function and quality of life.

Interventions

PROCEDURESurgery Alone

Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.

OTHERCombined Surgery and Radiation therapy

Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed diagnosis of malignancy other than lymphoma * Presence of femoral metastases at high risk of pathologic fracture (Mirels' score 8 or more) * At least 18 years of age * Able to provide written informed consent * Able to participate in follow-up

Exclusion criteria

* Surgical consultation for the purpose of obtaining a tissue/histological diagnosis only, not for treatment * Histological diagnosis of lymphoma

Design outcomes

Primary

MeasureTime frameDescription
To describe the ambulatory status at 3 months by intervention (surgery ± radiotherapy, and radiotherapy alone group) - Ambulatory status6 monthsPatient will be assessed at baseline, 6 weeks, 3 months and 6 months

Secondary

MeasureTime frameDescription
To describe patterns of management in patients with femoral metastases at high risk of pathological fracture - Perioperative Morbidity and Mortality for surgical patients; pain score and performance status; QOL6 monthsPatients will be assessed at baseline, 6 weeks, 3 months and 6 months
To describe patient and disease characteristics of major management groups (surgery ± radiotherapy, radiotherapy alone due to preference, radiotherapy alone due to co-morbid conditions) - Assessment of lower limb function6 monthsPatient will be assessed at baseline, 6 weeks, 3 months, and 6 months.

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORRebecca Wong, MB ChB

University Health Network, Princess Margaret Hospital

PRINCIPAL_INVESTIGATORPeter Ferguson, MD

Mount Sinai Hospital, Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026